Drugs / CWP232291
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02426723 | Oct 2015 → Oct 2018 | plasma cell myeloma | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01398462 | Jul 2011 → Dec 2015 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, myelofibrosis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03055286 | Feb 2017 → Aug 2025 | acute myeloid leukemia | JW Pharmaceutical | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CWP232291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02426723 ↗ |
| Known as | CWP291 | “CWP232291 (CWP291) is a small-molecule inhibitor of Wnt signaling that causes degradation of β-catenin via apoptosis induction through endoplasmic reticulum stress activation.” PMID 32396615 ↗ May 2020 |
| Action | Inhibit | “CWP232291 targets beta-catenin for degradation and thereby inhibits the expression of cell cycle and anti-apoptotic genes such as cyclin D1 and survivin.” NCT01398462 ↗ |
| Modality | Small molecule | “CWP232291 (CWP291) is a small-molecule inhibitor of Wnt signaling” PMID 32396615 ↗ May 2020 |
| Route | Intravenous | “IV Infusion” NCT01398462 ↗ |